Pharma & Biotech
Cardiol Therapeutics is advancing its proprietary pharmaceutical cannabidiol therapeutics program to treat life-threatening heart disease
Acasti Pharma eyeing FDA meeting as it continues to advance heart disease candidate CaPre
Acasti Pharma edging closer to commercializing CaPre as it eyes topline clinical data for Christmas
Only registered members can use this feature.
Copyright © Proactive Investors 2020.
All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC.